The effect of Curcumin on LP(a) and hs-CRP in diabetes patients and concurrent coronary artery diseases( coronary artery disease less than 50% obstruction)

The effects of Curcumin on serum level changes of lipoprotein (a) and hs-CRP as novel biomarkers in type 2 diabetic patients with coronary artery disease of less than 50% obstruction: A double-blind clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130811014330N4

Enrollment

Registered

2018-10-30

Start date

2017-08-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAD. Chronic ischaemic heart disease

Interventions

Intervention 1: The intervention group received routine treatment of heart disease and DMII in accordance with, the administration of curcumin. 1 Soft gel ((SinaCurcumin® (as nano-micelle 80 mg per da

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with coronary artery disease which were selected by cardiologist Male/ Female older than 18 years diabetic patients Coronary artery stenosis in angiography less than 50%

Exclusion criteria

Exclusion criteria: Pregnant and breast-feeding patients; Rheumatic disease; Chronic liver diseases; Renal diseases; Every types of malignancies; Infectious diseases in the last 3 months; Patients with any surgical procedures in the preceding 3 months; Subjects who had a history of angioplasty or coronary by-pass graft surgery; major trauma or an immunologic disease; Subjects who were using steroids, penicillin, oral contraceptive or hormone replacement therapy; Inflammatory bowel disease, psoriasis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, autoimmune thyroiditis.

Design outcomes

Primary

Measure	Time frame
Serum level of lipoprotein (a). Timepoint: at the baseline and 3 months after intervention. Method of measurement: ELISA.;Serum level of hs-CRP. Timepoint: at the baseline and 3 months after intervention. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
HbA1C. Timepoint: Before intervention and 3 months after intervention. Method of measurement: autoanalyzer bt3000.;Fast blood sugar (FBS). Timepoint: Before intervention and 3 months after intervention. Method of measurement: autoanalyzer bt3000.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Reza Rahimi

Mashhad University of Medical Sciences

rahimihr@mums.ac.ir+98 51 3800 2301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026